An interventional study of Transcutaneous Tibial Nerve Stimulation (TTNS) with the Cefar Uro Device in Overactive Bladder (OAB), Refractory Overactive Bladder and Urinary Urgency and Frequency, sponsored by DJO UK Ltd. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by DJO UK Ltd · Not applicable, Interventional, and Treatment
A Post-Market Prospective Clinical Investigation to collect PMCF data on the safety and performance of the Cefar URO device when using the preset program P4 (parameter setting: frequency 20Hz, pulse width 200μs) for the symptomatic treatment of urge incontinence in adults with overactive bladder in accordance with the approved labelling.
The Cefar URO device features four pre-set programs (P1, P2, P3 and P4) and three custom programs. Although supporting data on the preset programs P1, P2, P3 are available for the clinically equivalent UROstim2 device, program P4 is unique to Cefar URO. Program P4 utilizes the parameters 20Hz and 200μs which are commonly reported in the literature for the stated indications but for which no data is available for the clinically equivalent UROstim2 device. The present study is therefore aimed to cover this data gap.
The objectives of this prospective study are to assess the performance and safety of Cefar URO when used at home by enrolled patients using the P4 program pre-set parameters i.e. frequency 20Hz, pulse width 200μs, for 12 weeks.
Adult patients who require symptomatic treatment of urge incontinence and associated symptoms with overactive bladder (including refractory overactive bladder of idiopathic or neurogenic origin), will undergo Transcutaneous Posterior Tibial Nerve Stimulation with the Cefar URO device at home.
The diagnosis of OAB is made by the Investigator on the basis of clinical symptoms in routine practice.
The assessment of symptoms and quality of life of patients will be completed before treatment (Baseline) and after 6 and 12 weeks of treatment with the Cefar URO device. An additional assessment of the maintenance of symptoms and quality of life will be performed 4 weeks after end of the per protocol treatment.
The tests used to assess symptoms and quality of life are and compliance with treatment are:
The following parameters setting (preset program P4) will be used for treatment of all enrolled subjects with the Cefar URO device:
The electrodes will be placed in the medial ankle as according to the device IFU.
Patients will be asked to record each treatment session performed on the patient's diary, in order to assess compliance with the scheduled treatment plan.
The subjects will be treated for a period of 12 weeks with the Cefar URO device as per the treatment protocol described above.
After completion of the per protocol treatment period, the subjects will be followed up for an additional period of 4 weeks. During these four weeks, patients will be asked to continue performing the treatment according to their needs and according to the Investigator's instructions (Maintenance treatment protocol). No prescription about the number of treatments is imposed by the protocol during this period.
The subjects will be evaluated at study site for 6 on site visits and 10 weekly phone contacts, as detailed in the study flowchart at the end of this section.
Weekly follow-up phone contacts with the patients will be performed during the 12 weeks of the per protocol treatment with the exception of the weeks when an onsite visit is scheduled. One additional phone call will be performed during the exploratory long term 4 weeks follow up period (Maintenance period). These regular contacts serve to remind the patient to follow the treatment plan and to complete the self-reported questionnaires accurately. Additionally, at each phone contact patients will be asked to report if any issues/adverse events have been occurred since the last visit or phone contact. The regular phone contact with patients should help in keeping the adherence to the protocol and have a higher compliance to the treatment.
858 studies on the registry are indexed under Urinary Bladder, Overactive; 127 are open to participants now.
This study's planned enrollment of 53 is below the median of 70 across 649 interventional studies indexed under Urinary Bladder, Overactive.
Browse Urinary Bladder, Overactive studies →DJO UK Ltd is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will undergo Transcutaneous Posterior Tibial Nerve Stimulation with the Cefar URO device. The following parameters setting (preset program P4) will be used for treatment of all enrolled subjects: * frequency of 20Hz * pulse width of 200 μs * duration: 30 minutes per treatment. * treatment frequency: subjects will be recommended to have 7 treatment sessions per week for a total of 12 weeks (84 treatments total), and anyway no less that one treatment per week. The electrodes will be placed in the medial ankle as according to the device IFU.
Device: Transcutaneous Tibial Nerve Stimulation (TTNS) with the Cefar Uro Device
Transcutaneous Tibial Nerve Stimulation (TTNS) with the Cefar URO device using the preset program P4 (parameter setting: frequency 20Hz, pulse width 200μs) for the symptomatic treatment of urge incontinence in adults with overactive bladder in accordance with the approved labelling.
Incidence of Treatment-Emergent Adverse Events
\- adverse events/malfunctions/complications reported during the study. Subjects and Investigators will be prompted to record such issues on the AE evaluation form.
Time frame: From enrollment to the end of Treatment at 16 weeks.
Frequency of Overactive Bladder Symptoms
\- change in symptoms, at 12 weeks, quantified as the mean change from baseline on the Overactive Bladder-questionnaire-Short Form (OAB-q-SF), Symptoms bother scale (6 items) based on patient self-reporting. The lowest score for symptoms is 6, and the highest is 36. Higher score values are indicative of grater symptom bother and lower scores indicate minimal symptom bother. As per the literature (Zonic-Imamovic et al.,2021), we may expect an approximate mean reduction of the Symptoms Bother scale of 10.4 points at 12 weeks compared to the baseline measurement.
Time frame: From enrollment to the end of Treatment at 12 weeks.
Number of Urinary Urgency and Urinary Frequency Episodes
\- change in the number of episodes of Urinary Urgency and Urinary Frequency measured at 12 weeks compared to baseline, measured by means of 3-day bladder patient diary. This will quantify the average number of urgency and frequency episodes per day over three consecutive days, allowing for a direct comparison of baseline and 12-week data.
Time frame: From enrollment to the end of Treatment at 12 weeks.
Change in Quality of Life
\- change in Health-Related Quality of Life as shown by a reduction in the Overactive Bladder-questionnaire-Short Form (OAB-q-SF), Health-Related Quality of Life (HRQoL) (13 items) at 12 weeks relative to baseline, based on patient self reported outcomes. To assess the quality of life, the lowest score is 13 and the highest is 78. Higher scores will be indicative of better HRQL.
Time frame: From enrollment to the end of Treatment at 12 weeks.
Number of Urinary Incontinence and Nocturia episodes
\- change in the number of episodes of Urinary Incontinence and Nocturia, assessed at 12 weeks compared to baseline using a 3-day bladder diary. This endpoint will quantify the average daily episodes for both incontinence and nocturia across three consecutive days, enabling a direct comparison of baseline and 12-week data.
Time frame: From enrollment to the end of Treatment at 12 weeks.
Frequency of Overactive Bladder Symptoms at a longer term follow up
\- Maintenance of Symptoms Bother between 12 and 16 weeks, assessed using the Symptoms Bother Scale from the Overactive Bladder-questionnaire-Short Form (OAB-q-SF). Maintenance will be defined as no statistically significant worsening in symptom-related distress between 12 and 16 weeks. The lowest score for symptoms is 6, and the highest is 36. Higher score values are indicative of grater symptom bother and lower scores indicate minimal symptom bother.
Time frame: From enrollment to the end of Treatment at 16 weeks.
Change in Quality of Life at a longer term follow up
\- maintenance of Health-Related Quality of Life (HRQoL) between 12 and 16 weeks, measured using the HRQoL component of the Overactive Bladder-questionnaire-Short Form (OAB-q-SF). Maintenance will be defined as no statistically significant worsening in HRQoL scores over this period. To assess the quality of life, the lowest score is 13 and the highest is 78. Higher scores will be indicative of better HRQL.
Time frame: From enrollment to the end of Treatment at 16 weeks.
Frequency of Overactive Bladder Symptoms and Change in Quality of Life at a longer term follow up
\- Maintenance of urinary symptom severity between 12 and 16 weeks, measured using the 3-day bladder diary. Maintenance will be defined as no statistically significant increase in the average daily episodes of Urinary Urgency, Frequency, Incontinence, and Nocturia over three consecutive days..
Time frame: From enrollment to the end of Treatment at 16 weeks.
Change in symptoms of faecal incontinence
Change in faecal incontinence symptoms during the treatment period, assessed for patients who report faecal incontinence at baseline. Symptom change will be measured using a 6-point Likert scale (where 1 means "condition resolved" and 6 "condition significanty worsen") at 12 weeks, with analysis exploring whether peripheral neuromodulation yields a positive effect on urge faecal incontinence.
Time frame: From enrollment to the end of Treatment at 12 weeks.
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Oct 2026, 9 months after the start.
Of 41 industry-sponsored interventional studies with no phase under Urinary Bladder, Overactive, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 25. This study's planned 9 months is below that.
Counting every sponsor, half of 174 studies reached it within 19 months; a quarter within 10 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
DJO UK Ltd